MitoTEMPO
MitoTEMPO has been studied in 21 papers since 2016: 2 trials and 5 observational studies in people, 7 in animals, 5 in cells, 2 reviews; 6 in the past year. Its furthest trials in people are at phase 2. The newest paper, Sep 14, 2026: “Soluble pathogenic tau transmission to astrocytes drives cellular senescence and neurovascular uncoupling in a model…”.
1 new paper in 30 daysSee all 34 papers on MitoTEMPO
At a glance
The findings reach people, from one lab or study; independent labs found the same change in cells. 16 independent labs in 7 countries; 1 trial, none about aging.
“Likewise, Tempol improved Δ%CVCmax compared with Ringer’s (61.40 ± 15.92 vs. 37.02 ± 20.64, p = 0.01), but mitoTempo (44.36 ± 25.91, p = 0.69) did not.”
1 of its findings points the other way.
- 16 independent labs in 7 countries
- 1 finding against
- 1 trial, none about aging
- Funders: National Natural Science Foundation of China and others
- 2 of 37 findings with company ties
- Human trial2
- Humans5
- Animals7
- Cells5
Studies in people
2 studies gave MitoTEMPO to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on local heating-induced cutaneous vasodilation no change: Has no effect on nitric oxide-mediated cutaneous vasodilation up: Increases non-nitric oxide-mediated cutaneous vasodilation13.95 ± 16.43 versus 4.04 ± 6.14 %CVCmax | Trial | 15 peopleBoth67 ± 3 yrOlder adults; local heating at 42°C | American journal of physiology. Heart and circulatory physiology, May 11, 2026 |
no change: Has no effect on nitric oxide-dependent cutaneous vasodilation44.36 ± 25.91 vs. 37.02 ± 20.64 %CVCmax, p = 0.69 up: Improves non-nitric oxide-mediated cutaneous vasodilation13.95 ± 16.43 vs. 4.04 ± 6.14 %CVCmax, p < 0.01 | Randomized trial6 weeks | 16 peopleBoth67 ± 3 yrsOlder adults; during the placebo visit, compared with Ringer's | Physiology, May 1, 2026 |
What did studies of MitoTEMPO find?
31Studies of MitoTEMPO measured 31 outcomes; the most studied are cellular senescence (5 studies), non-nitric oxide-mediated cutaneous vasodilation (2) and apoptosis (2).
Cellular senescence
downin animals1downin cells1downin human cells1downin mouse cells1+1
5 studies
Cellular senescence
downin animals1downin cells1downin human cells1downin mouse cells1+1
MitoTEMPO decreases cellular senescence in human cells.
“suppression of mitochondrial ROS (mtROS) with mitoTEMPO reduces mtDNA leakage and STING activation, thereby attenuating HUVEC senescence.”
Cellshuman umbilical vein endothelial cell
Fat-derived protein worsened signs of vessel aging in mice
Aging cell
MitoTEMPO decreases cellular senescence in vitro and in vivo.
“Scavenging mitochondrial ROS with MitoTEMPO reduced tau-induced SASP cytokine and senescence-associated responses in vitro and in vivo”
Animalsin vitro and in vivo
bioRxiv : the preprint server for biologyPreprint
MitoTEMPO decreases cellular senescence in BMSCs from ovariectomized rats.
“Treatment with MitoTEMPO effectively reversed these effects, reinstating lysosomal functionality and suppressing the mitochondrial unfolded protein response (UPRmt).”
Cellsin BMSCs from ovariectomized rats
Journal of cellular physiology
MitoTEMPO decreases cellular senescence in mouse cells (high-glucose conditions, with or without Mdivi-1).
“MitoTempo inhibited HG-induced mitochondrial reactive oxygen species and cell senescence with or without Mdivi-1.”
Cellshigh-glucose conditions, with or without Mdivi-1renal tubular epithelial cell
Cell death & disease
MitoTEMPO decreases cellular senescence in VSMCs.
“zinc-induced senescence was reduced by inhibition of NF-κB or reduction of mitochondrial ROS with MitoTEMPO”
Cellsin VSMCs
Free radical biology & medicine
Non-nitric oxide-mediated cutaneous vasodilation
upin humans2
2 studies
Non-nitric oxide-mediated cutaneous vasodilation
upin humans2
MitoTEMPO increases non-nitric oxide-mediated cutaneous vasodilation in humans (local heating at 42°C; compared with Ringer's vehicle) (13.95 ± 16.43 versus 4.04 ± 6.14 %CVCmax).
“MitoTempo increased the non-NO-mediated component of the response compared with Ringer's (13.95 ± 16.43 vs. 4.04 ± 6.14; P < 0.01)”
Human triallocal heating at 42°C; compared with Ringer's vehiclecutaneous microvasculature1 mM7 male and 8 femalesn = 15
American journal of physiology. Heart and circulatory physiology
MitoTEMPO improves non-nitric oxide-mediated cutaneous vasodilation in humans during the placebo visit, compared with Ringer's (13.95 ± 16.43 vs. 4.04 ± 6.14 %CVCmax, p < 0.01).
“However, mitoTempo improved non-NO-mediated dilation compared with Ringer’s (13.95 ± 16.43 vs. 4.04 ± 6.14; p < 0.01), whereas Tempol did not (7.16 ± 7.55; p = 0.41).”
Human trialduring the placebo visit, compared with Ringer'sintradermal microdialysisskin1mMn = 16
Physiology
Apoptosis
no changein cells1downin mice1
2 studies
Apoptosis
no changein cells1downin mice1
MitoTEMPO showed no clear effect on apoptosis in lysosomal dysfunction-induced apoptosis, tested alongside diphenyleneiodonium.
“Lysosomal dysfunction-induced apoptosis in chondrocytes was not blocked by antioxidants MitoTempo or Diphenyleneiodonium (DPI)”
Cellsin lysosomal dysfunction-induced apoptosis, tested alongside diphenyleneiodonium
Osteoarthritis and cartilage
MitoTEMPO inhibits apoptosis in middle-aged Apoe-/-/Sod2+/- mice.
“decreasing smooth muscle cell apoptosis and matrix degradation”
Animalsin middle-aged Apoe-/-/Sod2+/- mice
Journal of the American Heart Association
Efferocytosis
upin human cells1
1 study
Efferocytosis
upin human cells1
MitoTEMPO improves efferocytosis in THP-1-derived macrophages under FIN-56 treatment.
“MitoTEMPO reduced mitochondrial ROS and improved efferocytosis”
Cellsin THP-1-derived macrophages under FIN-56 treatment
Rapamycin improves efferocytosis and reduces plaques in mice
International immunopharmacology
Phagocytosis
upin mice1
1 study
Phagocytosis
upin mice1
MitoTEMPO improves phagocytosis in mice.
“In a mouse model, MitoTEMPO significantly boosted the phagocytosis of peritoneal macrophages against bacteria.”
Animalsperitoneal macrophages
Aging Impairs Macrophage Phagocytosis Through Mitochondrial ROS-Induced Collagen Production
Aging cell
Nitric oxide-mediated cutaneous vasodilation
no changein humans1
1 study
Nitric oxide-mediated cutaneous vasodilation
no changein humans1
MitoTEMPO showed no clear effect on nitric oxide-mediated cutaneous vasodilation in humans (local heating at 42°C; compared with Ringer's vehicle).
“Tempol improved the NO contribution to the response compared with Ringer's (61.40 ± 15.92 vs. 37.02 ± 20.64, P = 0.01), but MitoTempo (P = 0.69) did not.”
Human triallocal heating at 42°C; compared with Ringer's vehiclecutaneous microvasculature1 mM7 male and 8 femalesn = 15
American journal of physiology. Heart and circulatory physiology
Local heating-induced cutaneous vasodilation
no changein humans1
1 study
Local heating-induced cutaneous vasodilation
no changein humans1
MitoTEMPO showed no clear effect on local heating-induced cutaneous vasodilation in humans (local heating at 42°C; compared with Ringer's vehicle).
“Tempol improved the local heating response compared with Ringer's (76.37 ± 18.99 vs. 51.07 ± 23.36, P = 0.02), but MitoTempo (P = 0.25) did not.”
Human triallocal heating at 42°C; compared with Ringer's vehiclecutaneous microvasculature1 mM7 male and 8 femalesn = 15
American journal of physiology. Heart and circulatory physiology
Nitric oxide-dependent cutaneous vasodilation
no changein humans1
1 study
Nitric oxide-dependent cutaneous vasodilation
no changein humans1
MitoTEMPO showed no clear effect on nitric oxide-dependent cutaneous vasodilation in humans during the placebo visit, compared with Ringer's (44.36 ± 25.91 vs. 37.02 ± 20.64 %CVCmax, p = 0.69).
“Likewise, Tempol improved Δ%CVCmax compared with Ringer’s (61.40 ± 15.92 vs. 37.02 ± 20.64, p = 0.01), but mitoTempo (44.36 ± 25.91, p = 0.69) did not.”
Human trialduring the placebo visit, compared with Ringer'sintradermal microdialysisskin1mMn = 16
Physiology
TP53
downin rats1
1 study
TP53
downin rats1
MitoTEMPO decreases TP53 in trabecular bone region of the proximal tibia of ovariectomized rats.
“reduced the expression of p53, HSP60, and CLPP in the trabecular bone region of the proximal tibia.”
Animalsin trabecular bone region of the proximal tibia of ovariectomized ratsbone
Journal of cellular physiology
Trabecular bone loss
downin rats1
1 study
Trabecular bone loss
downin rats1
MitoTEMPO decreases trabecular bone loss in ovariectomized rats.
“MitoTEMPO administration in OVX rats curtailed trabecular bone loss”
Animalsin ovariectomized rats
Journal of cellular physiology
All 31Fewer
Has MitoTEMPO been tested in people?
0 of 1 about agingYes: 2 trials and 5 observational studies in people have been published, and 1 trial is registered.
In trials
Phase 2Recruiting1 trial
Phase 2Recruiting1 trial
Trial sponsors
1 trialPhase 260 people